Sales of implants are set to fall sharply as non-urgent procedures are deferred.
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
Digital health is a core focus for Philips. Might more acquisitions be on the way?
Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.